single1MG
IGF-1 LR3
1MG Protocol
IGF-1 LR3 1MG
Injection Freq.
Inject once daily
Cycle Sched.
8 weeks is standard; 12-week protocols exist but may show diminished returns beyond Week 6–8
Reconstitution
3.0 mL BAC water
Enhanced anabolic signaling and protein synthesis (research observation)
Extended bioavailability vs native IGF-1 due to reduced binding-protein interaction
Metabolic effects via IGF-1 receptor pathways
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 20 mcg (0.02 mg) | 6 |
| 2 | Weeks 3–4 | 40 mcg (0.04 mg) | 12 |
| 3 | Weeks 5–8 | 50 mcg (0.05 mg) | 15 |
Inject once daily
8 weeks is standard; 12-week protocols exist but may show diminished returns beyond Week 6–8
IGF-1 LR3 is a modified analog of human insulin-like growth factor-1 engineered to circulate longer and act more consistently than native IGF-1. The protocol describes two key structural changes—an N-terminal extension and a substitution at position 3—that reduce binding to IGF-binding proteins. With less sequestration by binding proteins, the peptide remains bioavailable for longer, extending its effective half-life from minutes (native IGF-1) to several hours and supporting more stable exposure across the day. Functionally, IGF-1 LR3 signals through the IGF-1 receptor, a pathway linked in research to anabolic signaling, protein synthesis, cellular growth processes, and metabolic regulation. Because IGF signaling has insulin-like actions, the page emphasizes that glucose effects are a central safety consideration and that responses can be dose- and duration-dependent in research settings.
Hypoglycemia risk (shakiness, confusion, sweating, dizziness)
Mild injection-site irritation/redness/discomfort
Dose-dependent safety concerns at higher doses
Receptor desensitization/diminished response with prolonged continuous use
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)